Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 4/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27201918 | 0.89 | ACHE (0.53) | ACHEPKMMMP2ALDH1A1POLB | |
| SCHEMBL537069 | 0.81 | ACHE (0.69) | ACHEPKMMMP2ALDH1A1POLB | |
| SCHEMBL2690876 | 0.81 | ACHE (0.74) | ACHEPKMMMP2ALDH1A1POLB | |
| SCHEMBL2600494 | 0.80 | ACHE (0.67) | ACHEPKMMMP2ALDH1A1POLB | |
| SCHEMBL29705053 | 0.78 | ACHE (0.44) | ACHEPKMMMP2ALDH1A1POLB | |
| SCHEMBL13830631 | 0.77 | ACHE (0.58) | ACHEPKMMMP2ALDH1A1POLB | |
| SCHEMBL760022 | 0.77 | ACHE (0.54) | ACHEPKMMMP2ALDH1A1POLB | |
| SCHEMBL13812162 | 0.77 | ACHE (0.68) | ACHEPKMMMP2ALDH1A1POLB | |
| SCHEMBL14538647 | 0.74 | ACHE (0.86) | ACHEPKMMMP2ALDH1A1POLB | |
| SCHEMBL12169285 | 0.74 | ACHE (0.86) | ACHEPKMMMP2ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4539855-A1 | BORON CONTAINING PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | Borah, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119343143-A | Boron-containing pyrimidine compounds, compositions containing them, methods and uses thereof | 博拉公司 | 2025-01-21 | — | — | CN | disclosed |
| US-20240132525-A1 | BORON CONTAINING PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2024-04-25 | — | — | US | disclosed |
| WO-2023244775-A1 | BORON CONTAINING PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | Boehringer Ingelheim Animal Health USA Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132525-A1 | BORON CONTAINING PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | JAK2, JAK1, JAK3 | ACHE 4351/4885PKM 2130/4885MMP2 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.